| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1898bb1665d8564a7186068aabd15dd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eabf3970aa0c7c010a71dcf3aee652a0 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-00 |
| filingDate |
2001-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6869090311c8a70b9d331af2ea40397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90782b475e7573f54fa93e4e25d6e640
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1136d42b981c8d1743e60914c7a99bca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2d3f06668afe917e700915b58dcd699 |
| publicationDate |
2002-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2194541-C1 |
| titleOfInvention |
Method for treating locally generalized stomach cancer by applying combined therapy |
| abstract |
FIELD: medicine. SUBSTANCE: method involves administering two systemic polychemotherapy courses with 3 weeks long pause between the courses. The following treatment schedule is suggested. Metotrexate is intravenously administered at a dose of 5mg/m 2 as bolus dose from the first to the fifth day. Carboplatin is administered at a dose of 50mg/m 2 as 45 min long intravenous infusion from the first to the fifth day. 5-fluorouracyl is administered at a dose of as 3 h long intravenous infusion from the first to the fifth day. Surgical intervention is carried out 3 weeks later, after the polychemotherapy course being over. Cisplatin is administered at a dose of 15mg/m 2 during the operation. EFFECT: enhanced effectiveness in treating III stage stomach cancer cases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2706346-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2461375-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2696534-C1 |
| priorityDate |
2001-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |